Literature DB >> 3498582

Cerebrospinal fluid interleukin 1 like activity during chronic relapsing experimental allergic encephalomyelitis.

J A Symons1, R V Bundick, A J Suckling, M G Rumsby.   

Abstract

Cerebrospinal fluid (CSF) and plasma samples were taken from strain 13 guinea pigs in various stages of chronic relapsing experimental allergic encephalomyelitis (CREAE). The samples were assayed for interleukin 1 (IL-1) in the C3H/Hej mouse thymocyte assay. After removal of inhibitors, IL-1 was detectable in low amounts in plasma (5 U/ml) throughout the course of the disease but was raised in the acute phase (12 U/ml). CSF IL-1 was, however, only present in low amounts (6 U/ml) during the acute phase but was elevated (18 U/ml) during the chronic stages of CREAE. During the relapse phase levels of IL-1 correlated with the total leucocyte count in the CSF. On gel filtration of CSF, IL-1 activity eluted at approximately 15 kD and could not be attributed to leakage of plasma IL-1 during CSF puncture or IL-2 activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498582      PMCID: PMC1542740     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Interferon in the serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders.

Authors:  M Degré; H Dahl; B Vandvik
Journal:  Acta Neurol Scand       Date:  1976-02       Impact factor: 3.209

2.  Chronic relapsing experimental allergic encephalomyelitis: an experimental model of multiple sclerosis.

Authors:  H M Wiśniewski; A B Keith
Journal:  Ann Neurol       Date:  1977-02       Impact factor: 10.422

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Chronic relapsing experimental allergic encephalomyelitis. The presence in the cerebrospinal fluid of factors chemotactic for monocytes.

Authors:  J A Kirby; A J Suckling; M G Rumsby
Journal:  J Neuroimmunol       Date:  1983-12       Impact factor: 3.478

5.  Characterization of fibroblast proliferation factors elaborated by antigen- and mitogen-stimulated guinea pig lymph node cells: differentiation from lymphocyte-derived chemotactic factor for fibroblasts, lymphocyte mitogenic factor, and interleukin 1.

Authors:  A E Postlethwaite; A H Kang
Journal:  Cell Immunol       Date:  1982-10       Impact factor: 4.868

6.  Chronic relapsing experimental allergic encephalomyelitis: cerebrospinal fluid cytology and a comparison with meningeal and spinal cord pathology.

Authors:  A J Suckling; N R Wilson; J A Kirby; M G Rumsby
Journal:  Neuropathol Appl Neurobiol       Date:  1983 May-Jun       Impact factor: 8.090

7.  Suboccipital puncture of guinea pigs.

Authors:  H Reiber; O Schunck
Journal:  Lab Anim       Date:  1983-01       Impact factor: 2.471

8.  Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells.

Authors:  A Fontana; F Kristensen; R Dubs; D Gemsa; E Weber
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

9.  Thymoma production of T cell growth factor (Interleukin 2).

Authors:  J J Farrar; J Fuller-Farrar; P L Simon; M L Hilfiker; B M Stadler; W L Farrar
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

10.  Optimum conditions for inducing chronic relapsing experimental allergic encephalomyelitis in guinea pigs.

Authors:  A B Keith; J R McDermott
Journal:  J Neurol Sci       Date:  1980-06       Impact factor: 3.181

View more
  11 in total

1.  Pathophysiologic effect of interleukin-1b in the rabbit retina.

Authors:  J A Martiney; M Litwak; J W Berman; J C Arezzo; C F Brosnan
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

2.  Regulation of brain interleukin-1 beta (IL-1 beta) system mRNAs in response to pathophysiological concentrations of IL-1 beta in the cerebrospinal fluid.

Authors:  S E Ilyin; G Sonti; D Gayle; C R Plata-Salamán
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

Review 3.  New Insights into the Role of IL-1β in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.

Authors:  Chih-Chung Lin; Brian T Edelson
Journal:  J Immunol       Date:  2017-06-15       Impact factor: 5.422

4.  Adenosine: a mediator of interleukin-1beta-induced hippocampal synaptic inhibition.

Authors:  W P Luk; Y Zhang; T D White; F A Lue; C Wu; C G Jiang; L Zhang; H Moldofsky
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

5.  In vitro study of mediators of inflammation in multiple sclerosis.

Authors:  J E Merrill; S R Strom; G W Ellison; L W Myers
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

6.  Lymphocyte activating factor activity in the serum and cerebrospinal fluid of patients with multiple sclerosis.

Authors:  D Donati; P Annunziata; G C Guazzi; D Boraschi; A Tagliabue
Journal:  Ital J Neurol Sci       Date:  1990-02

7.  Distinct CD40L receptors mediate inflammasome activation and secretion of IL-1β and MCP-1 in cultured human retinal pigment epithelial cells.

Authors:  Zong-Mei Bian; Matthew G Field; Susan G Elner; J Michelle Kahlenberg; Victor M Elner
Journal:  Exp Eye Res       Date:  2018-02-16       Impact factor: 3.467

8.  Differential Roles of Dendritic Cells in Expanding CD4 T Cells in Sepsis.

Authors:  Samuel Darkwah; Nodoka Nago; Michael G Appiah; Phyoe Kyawe Myint; Eiji Kawamoto; Motomu Shimaoka; Eun Jeong Park
Journal:  Biomedicines       Date:  2019-07-18

9.  OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis.

Authors:  Alba Sánchez-Fernández; Damaris B Skouras; Charles A Dinarello; Rubèn López-Vales
Journal:  Front Immunol       Date:  2019-11-01       Impact factor: 7.561

10.  IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8.

Authors:  Alba Sánchez-Fernández; Stephanie Zandee; Jesús Amo-Aparicio; Marc Charabati; Alexandre Prat; Cecilia Garlanda; Elan Z Eisenmesser; Charles A Dinarello; Rubèn López-Vales
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.